Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 8 Neoplasm Metastasis 3 Neoplasms 2 Carcinoma, Pancreatic Ductal 2 Adenocarcinoma 2 Thromboembolism 1 Stomach Neoplasms 1 Recurrence 1 Pancreatic Ductal Adenocarcinoma 1 Pancreatic Adenocarcinoma 1 Metastatic Pancreatic Adenocarcinoma 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Carboplatin 784 Pemetrexed 607 Cisplatin 545 Paclitaxel 491 pembrolizumab 464 Docetaxel 440 Gemcitabine 328 Erlotinib Hydrochloride 307 Radiotherapy 258 Nivolumab 244 Bevacizumab 233 osimertinib 178 Drug Therapy 164 durvalumab 157 atezolizumab 135 Gefitinib 134 Radiosurgery 133 Vinorelbine 111 Cetuximab 97 130-nm albumin-bound paclitaxel 94 Ipilimumab 86 Magnetic Resonance Spectroscopy 84 Taxes 79 Surgical Procedures, Operative 74 Afatinib 68 Albumin-Bound Paclitaxel 66 Specimen Handling 61 Etoposide 61 Cyclophosphamide 60 tislelizumab 59

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × PEGPH20 × Clear all

NCT02346370 2019-02-08

PRIMAL

Halozyme Therapeutics

Phase 1 Terminated

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡